Yoshihiro Nishikawa

Yoshihiro Nishikawa

Auto-generated profile, based on publicly available information

Yoshihiro Nishikawa

Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2016 in Gut
Verified
Journal Article
Closed access
PDF file
MSMasahiro Shiokawa
Masahiro Shiokawa
YKYuzo Kodama
Yuzo Kodama
KKKatsutoshi Kuriyama
Katsutoshi Kuriyama
KYKenichi Yoshimura
Kenichi Yoshimura
TTTeruko Tomono
Teruko Tomono
TCTsutomu Chiba
Tsutomu Chiba
Objective IgG4-related disease (IgG4-RD) is a systemic disease characterised by elevated serum IgG4 and IgG4-positive lymphoplasmacytic infiltration in the affected tissues. The pathogenic role of IgGs, including IgG4, in patients with IgG4-RD, however, is unknown. Design We examined the pathogenic activity of circulating IgGs in patients with IgG4-RD by injecting their IgGs into neonatal male Balb/c mice. Binding of patient IgGs to pancreatic tissue was also analysed in an ex vivo mouse organ culture model and in tissue samples from patients with autoimmune pancreatitis (AIP). Results Subcutaneous injection of patient IgG, but not control IgG, resulted in pancreatic and salivary gland injuries. Pancreatic injury was also induced by injecting patient IgG1 or IgG4, with more destructive changes induced by IgG1 than by IgG4. The potent pathogenic activity of patient IgG1 was significantly inhibited by simultaneous injection of patient IgG4. Binding of patient IgG, especially IgG1 and IgG4, to pancreatic tissue was confirmed in both the mouse model and AIP tissue samples. Conclusions IgG1 and IgG4 from patients with IgG4-RD have pathogenic activities through binding affected tissues in neonatal mice.

8 August 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MSMasahiro Shiokawa
Masahiro Shiokawa
YKYuzo Kodama
Yuzo Kodama
KSKiyotoshi Sekiguchi
Kiyotoshi Sekiguchi
TKTakeshi Kuwada
Takeshi Kuwada
TTTeruko Tomono
Teruko Tomono
TCTsutomu Chiba
Tsutomu Chiba
The extracellular matrix protein laminin 511 is an autoantigen involved in the pathophysiology of autoimmune pancreatitis.

9 August 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SHShigeru Hashimoto
Shigeru Hashimoto
SFShotaro Furukawa
Shotaro Furukawa
AHAri Hashimoto
Ari Hashimoto
ATAkio Tsutaho
Akio Tsutaho
AFAkira Fukao
Akira Fukao
HSHisataka Sabe
Hisataka Sabe
Although KRAS and TP53 mutations are major drivers of pancreatic ductal adenocarcinoma (PDAC), the incurable nature of this cancer still remains largely elusive. ARF6 and its effector AMAP1 are often overexpressed in different cancers and regulate the intracellular dynamics of integrins and E-cadherin, thus promoting tumor invasion and metastasis when ARF6 is activated. Here we show that the ARF6–AMAP1 pathway is a major target by which KRAS and TP53 cooperatively promote malignancy. KRAS was identified to promote eIF4A-dependent ARF6 mRNA translation, which contains a quadruplex structure at its 5′-untranslated region, by inducing TEAD3 and ETV4 to suppress PDCD4; and also eIF4E-dependent AMAP1 mRNA translation, which contains a 5′-terminal oligopyrimidine-like sequence, via up-regulating mTORC1. TP53 facilitated ARF6 activation by platelet-derived growth factor (PDGF), via its known function to promote the expression of PDGF receptor β (PDGFRβ) and enzymes of the mevalonate pathway (MVP). The ARF6–AMAP1 pathway was moreover essential for PDGF-driven recycling of PD-L1, in which KRAS, TP53, eIF4A/4E-dependent translation, mTOR, and MVP were all integral. We moreover demonstrated that the mouse PDAC model KPC cells, bearing KRAS/TP53 mutations, express ARF6 and AMAP1 at high levels and that the ARF6-based pathway is closely associated with immune evasion of KPC cells. Expression of ARF6 pathway components statistically correlated with poor patient outcomes. Thus, the cooperation among eIF4A/4E-dependent mRNA translation and MVP has emerged as a link by which pancreatic driver mutations may promote tumor cell motility, PD-L1 dynamics, and immune evasion, via empowering the ARF6-based pathway and its activation by external ligands. Significance Pancreatic ductal carcinomas (PDACs) have been extensively studied regarding their genomic alterations, microenvironmental intercommunication, and metabolic reprogramming. However, identification of the protein machinery of tumor cells that eventually drives malignancy as a result of driver mutations, and their associated events, is highly anticipated toward the development of precision medicine. The lack of such information regarding PDACs has hindered the elucidation of mechanisms driving malignancies, leaving them incurable. Here we demonstrated that the 2 well-known pancreatic driver mutations cooperatively activate a specific signaling pathway that promotes tumor invasion and immune evasion properties. Our results provide insights into the molecular basis by which malignancies often develop in parallel with oncogenesis and PDAC cell growth, as well as druggable targets for immunotherapies.

31 January 2019 in Oncogene
Verified
Journal Article
Closed access
PDF file
YNYoshihiro Nishikawa
Yoshihiro Nishikawa
YKYuzo Kodama
Yuzo Kodama
MSMasahiro Shiokawa
Masahiro Shiokawa
TMTomoaki Matsumori
Tomoaki Matsumori
SMSaiko Marui
Saiko Marui
HSHiroshi Seno
Hiroshi Seno

1 May 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
APAmelie Perron
Amelie Perron
YNYoshihiro Nishikawa
Yoshihiro Nishikawa
JIJun Iwata
Jun Iwata
HSHiromi Shimojo
Hiromi Shimojo
JTJunichiro Takaya
Junichiro Takaya
MUMotonari Uesugi
Motonari Uesugi
The transcription factor Hes family basic helix-loop-helix transcription factor 1 (Hes1) is a downstream effector of Notch signaling and plays a crucial role in orchestrating developmental processes during the embryonic stage. However, its aberrant signaling in adulthood is linked to the pathogenesis of cancer. In the present study, we report the discovery of small organic molecules (JI051 and JI130) that impair the ability of Hes1 to repress transcription. Hes1 interacts with the transcriptional corepressor transducing-like enhancer of split 1 (TLE1) via an interaction domain comprising two tryptophan residues, prompting us to search a chemical library of 1,800 small molecules enriched for indole-like π-electron–rich pharmacophores for a compound that blocks Hes1-mediated transcriptional repression. This screening identified a lead compound whose extensive chemical modification to improve potency yielded JI051, which inhibited HEK293 cell proliferation with an EC50 of 0.3 μm. Unexpectedly, using immunomagnetic isolation and nanoscale LC-MS/MS, we found that JI051 does not bind TLE1 but instead interacts with prohibitin 2 (PHB2), a cancer-associated protein chaperone. We also found that JI051 stabilizes PHB2's interaction with Hes1 outside the nucleus, inducing G2/M cell-cycle arrest. Of note, JI051 dose-dependently reduced cell growth of the human pancreatic cancer cell line MIA PaCa-2, and JI130 treatment significantly reduced tumor volume in a murine pancreatic tumor xenograft model. These results suggest a previously unrecognized role for PHB2 in the regulation of Hes1 and may inform potential strategies for managing pancreatic cancer.

18 May 2021 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
GPGyanu Parajuli
Gyanu Parajuli
MTMurat Tekguc
Murat Tekguc
JWJames B. Wing
James B. Wing
AHAri Hashimoto
Ari Hashimoto
DODaisuke Okuzaki
Daisuke Okuzaki
SHShigeru Hashimoto
Shigeru Hashimoto
The acquisition of mesenchymal traits leads to immune evasion in various cancers, but the underlying molecular mechanisms remain unclear. In this study, we found that the expression levels of AT-rich interaction domain-containing protein 5a (Arid5a), an RNA-binding protein, were substantially increased in mesenchymal tumor subtypes. The deletion of Arid5a in tumor cell lines enhanced antitumor immunity in immunocompetent mice, but not in immunodeficient mice, suggesting a role for Arid5a in immune evasion. Furthermore, an Arid5a-deficient tumor microenvironment was shown to have robust antitumor immunity, as manifested by suppressed infiltration of granulocytic myeloid-derived suppressor cells and regulatory T cells. In addition, infiltrated T cells were more cytotoxic and less exhausted. Mechanistically, Arid5a stabilized Ido1 and Ccl2 mRNAs and augmented their expression, resulting in enhanced tryptophan catabolism and an immunosuppressive tumor microenvironment. Thus, our findings demonstrate the role of Arid5a beyond inflammatory diseases and suggest Arid5a as a promising target for the treatment of immunotolerant malignant tumors.See related Spotlight by Van den Eynde, p. 854.